Treatment Of Topiramate In Pediatric Migraine: A Clinical Study

ObjectiveMigraine is one of the common diseases in nervous system and its etiology is still not very clear. Topiramate is approved for the prevention treatment of migraine in foreign countries. However, there are few domestic studies about the use of topiramae in migraine. The purpose of this article is to evaluate the treatment effect of topiramate and flunarizine in pediatric migraine, investigate their efficacy and safety, and compares with the differences.MethodsFrom June to December in 2007, Sixty patients with a diagnosis of migraine in out-patient clinic (OPD) of Shandong Provincial Hospital (SDPH) were randomly assigned to topiramate( n = 30, male 17, female 13, average age 9.1 years)and flunarizine ( n = 30, male 16, female 14, average age 9. 3 years ) groups.The medicine treatment regularly and sufficiently lasted for 3-monthst treatment phase. The outcome parameters examined included a mean monthly migraine frequency, migraine time , migraine severity and migraine index. After different treatments, following data were compared between topiramate and flunarizine : a mean monthly migraine frequency , migraine time , migraine severity and migraine index.The results were analyzed with SPSS 13.0 software.Results 1. There is no statistical significance in a mean monthly migraine frequency between topiramate group and flunarizine group before treatment (P>0. 05).2. There is statistical significance in a mean monthly migraine frequency in topiramate group and flunarizine group after treatment than before (P<0.01).3. There is statistical significance in a mean monthly migraine frequency between topiramate group and flunarizine group after treatment (P<0.05).4. There is no statistical significance in the migraine time between topiramate group and flunarizine group before treatment (P>0. 05).5. There is statistical significance in the migraine time between topiramate group and flunarizine group after treatment than before (P<0. 01).6. There is statistical significance in the migraine time between topiramate group and flunarizine group after treatment (P<0. 05).7. There is no statistical significance in the migraine severity between topiramate group and flunarizine group before treatment (P>0. 05).8. There is statistical significance in the migraine severity in topiramate group and flunarizine group after treatment than before (P<0. 01).9. There is statistical significance in the migraine severity between topiramate group and flunarizine group after treatment (P<0.01).10.There is no statistical significance in the migraine index between topiramate group and flunarizine group before treatment (P>0. 05).11.There is statistical significance in the migraine index between topiramate group and flunarizine group after treatment than before (P<0. 01).12.There is statistical significance in the migraine index between topiramate group and flunarizine group after treatment (P<0. 01).Conclusions 1.Both topiramate and flunarizine are potentially effective prophylaxis and treatment for children with migraine episodes.2. The effect of topiramate treatment for children with migraine episodes may be especially better.